I think CYP is a great pick to recover.
It's holding up well and proves that compared to the likes of FTT, POH, IIL etc, it's not a 1 hit wonder...but a tech platform in a very very new cell area.
Still 6 bags + on RTO.
Fuji likely to take less than the new timeline, and that's just a small indication. I think the whole Fuji thing has clouded the other targets, like CLI, OA, Asthma and wound care all progressing to Phase 2....so is just an opportunity ST
i still hold plenty (in T40)
- Forums
- Commodities
- Biotech Analysts $4M pa
I think CYP is a great pick to recover.It's holding up well and...
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)